Abstract: A fuel cell vehicle thermal management system with cold start function includes a fuel cell stack, electronic water pump, electronic thermostat, cold start heater and first solenoid valve, all connected to a thermal management controller, and air intake preheating heat exchangers. The coolant outlet of the fuel cell stack is connected with an inlet of the electronic water pump, and an outlet of the electronic water pump is connected with the inlets of the electronic thermostat and the first solenoid valve. The first outlet of the electronic thermostat is connected with the inlet of the heater. The outlet of the heater is connected with the inlet of the fuel cell stack. The outlet of the first solenoid valve is connected with the inlet of the intake preheating heat exchanger. The outlet of the intake preheating heat exchanger is connected with the inlet of the heater.

Abstract: Techniques are disclosed for using a trained machine learning (ML) pipeline to identify categories associated with target data items even though the identified categories may not already be present in the hierarchy. The ML pipeline may include trained cluster-based and classification-based machine learning models, among others. If the results of the cluster-based and classification-based machine learning models are the same, then the target data items is assigned to a hierarchical classification consistent with the identical results of the machine learning model. An assigned hierarchical classification may be validated by the operation of subsequent trained ML models that determine whether parent and child categories in the identified classification are properly associated with one another.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: The invention relates to a sampling method and system for path planning of a mobile robot in a man-machine environment, including: calculating a distance between a node and the closest obstacle on a map, simultaneously detecting a pedestrian in an environment and marking a position of the pedestrian; selecting a starting point position as a root node, and initializing a search tree; choosing a candidate node in a passable region, calculating a cumulative cost from a node to the candidate node, and choosing a node with the lowest cost as a growth node; performing collision detection on a connecting line between the growth and the candidate nodes, and determining whether collision detection succeeds; connecting the candidate node to the growth node, and determining whether the candidate node is a goal; and acquiring a node connecting line set from the root node to the goal to form a final path.

Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Abstract: A fuel cell vehicle thermal management system with cold start function, which includes a fuel cell stack, an electronic water pump, an electronic thermostat, a cold start heater, a first solenoid valve, a thermal management controller, and the air intake preheating heat exchangers. The electronic water pump, electronic thermostat, cold start heater, and the first solenoid valve are all electrically connected to the thermal management controller. The coolant outlet of the fuel cell stack is connected with the liquid inlet of the electronic water pump, and the liquid outlet of the electronic water pump is connected with the liquid inlet of the electronic thermostat and the liquid inlet of the first solenoid valve. The first liquid outlet of the electronic thermostat is connected with the liquid inlet of the cold start heater. The liquid outlet of the cold start heater is connected with the liquid inlet of the fuel cell stack.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Abstract: A dry dual-scroll vacuum pump includes a driving assembly and an upper cover located above the driving assembly, wherein the driving assembly includes an output shaft, and a movable disk is eccentrically arranged on the output shaft; two groups of first scroll teeth that are centrally symmetrical are arranged on a side of the movable disk that faces the upper cover; a fixed disk is arranged at a lower end of the upper cover, second scroll teeth that are in one-to-one correspondence with the first scroll teeth are arranged on the fixed disk, and the first scroll teeth are meshed with the second scroll teeth to form a compression cavity; and the upper cover is further provided with an air inlet and an air outlet, which correspond to the compression cavity.

Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.